121102-88-3

Usage

Uses

Used in Pharmaceutical Synthesis:
N-Boc-2-bromo-1-propanamine is utilized as an intermediate in the synthesis of various pharmaceuticals. The N-Boc group temporarily protects the amine group, allowing for selective reactions to occur at other sites on the molecule. Once the desired modifications are complete, the N-Boc group can be removed to reveal the free amine, enabling further reactions or the formation of the final product.
Used in Agrochemical Production:
In the agrochemical industry, N-Boc-2-bromo-1-propanamine serves as a key intermediate for the synthesis of various agrochemicals. The bromine atom in the compound can be used for further functionalization, allowing for the development of new compounds with improved properties, such as enhanced pest control or reduced environmental impact.
Used in Organic Synthesis:
N-Boc-2-bromo-1-propanamine is a versatile building block in organic synthesis, enabling the creation of a wide range of organic compounds. The N-Boc group provides a means to protect the amine group during reactions, while the bromine atom offers opportunities for further functionalization. This combination makes it an invaluable precursor for the synthesis of various organic molecules with diverse applications.

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 78-96-6 3-amino-2-propanol 
• 95656-86-3 tert-butyl 2-hydroxypropylcarbamate 
• 847259-93-2 (R)-1-((tert-butoxycarbonyl)amino)propan-2-yl methanesulfonate 

Downstream Products

• 1438409-77-8 (Z)-tert-butyl (2-(5-(4-ethoxybenzylidene)-2,4-dioxothiazolidin-3-yl)propyl)carbamate 

Relevant academic research and scientific papers

GLYCOSAMINOGLYCAN DERIVATIVE AND METHOD FOR PRODUCING SAME

The present invention provides a glycosaminoglycan derivative in which a group derived from glycosaminoglycan and a group derived from a physiologically active substance having at least one of a carboxy group and a hydroxy group are coupled by covalent bond with a spacer therebetween, in which the spacer is selected in accordance with the decomposition rate of the covalent bond to the group derived from the physiologically active substance.

TRPM8 receptor antagonists

Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula: whereinR is selected from: - H, CN, NO2, SO2NH2, SO2NHR' and SO2NR'2, where R' is selected from linear or branched C1-C4 alkyl;X is selected from: - F, Cl, CH3, NH2 and OHY is selected from: - O, CH2, NH and SO2R1, R2, R3 and R4, indipendently one from the other, are selected from - H and linear or branched C1-C4 alkyl;Z is selected from: - NR6 and R6R7N+, where R6 and R7 indipendently one from the other, are selected from: ? H and linear or branched C1-C4 alkylR5 is a residue selected from: - H and linear or branched C1-C4 alkylHet is a heteroaryl group selected from - a substituted or not substituted pyrrolyl, a substituted or not substituted N-methylpyrrolyl, a substituted or not substituted thiophenyl, a substituted or not substituted furanyl and a substituted or not substituted pyridinyl. Said compounds are useful in the treatment of pathologies depending on TRPM8 activity such as pain, cancer, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions, urological disorders.

TRPM8 RECEPTOR ANTAGONISTS

Compounds acting as selective antagonists of Transient Receptor Potential cation channel subfamily M member 8 (hereinafter referred to as TRPM8), having formula (I), wherein R is selected from: - H, Br, CN, NO2, SO2NH2, SO2NHR' and SO2NR'2, where R' is selected from linear or branched C1-C4 alkyl; X is selected from: - F, C1, C1-C3 alkyl, NH2 and OH Y is selected from: - O, CH2, NH and SO2 R1 and R2, independently one from the other, are selected from - H, F and linear or branched C1-C4 alkyl; R3 and R4, independently one from the other, are selected from - H and linear or branched C1-C4 alkyl; Z is selected from: - NR6 and R6R7N+, where R6 and R7 independently one from the other, are selected from: ? H and linear or branched C1-C4 alkyl R5 is a residue selected from: - H and linear or branched C1-C4 alkyl Het is a heteroaryl group selected from - a substituted or not substituted pyrrolyl, a substituted or not substituted N- methylpyrrolyl, a substituted or not substituted thiophenyl, a substituted or not substituted furyl and a substituted or not substituted pyridinyl. Said compounds are useful in the prevention and treatment of pathologies depending on TRPM8 activity such as pain, inflammation, ischaemia, neurodegeneration, stroke, psychiatric disorders, inflammatory conditions and urological disorders.

ETHER DERIVATIVE

The present invention relates to an ether derivative represented by the formula (I), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description, and an ether derivative represented by the formula (III), a pharmaceutically acceptable salt thereof, a hydrate thereof or a solvate thereof wherein each symbol is as defined in the description; a pharmaceutical composition containing the ether derivative; and a package containing the pharmaceutical composition and a description of use thereof. A pharmaceutical composition of the present invention, which contains this compound of the present invention has a superior anti-inflammatory and analgesic activity and is useful as various pharmaceutical agents such as an anti-inflammatory agent, an analgesic, a therapeutic agent for inflammatory bowel disease, a therapeutic agent for pollakiuria and/or incontinentia, a therapeutic agent for asthma and the like.

Cephalosporin compound and pharmaceutical composition thereof

Cephalosporin compounds represented by the general formula (I): STR1 wherein R1 and R5 independently represent a hydrogen atom or a protective group for an amino group; R2 represents an alkyl group or a cycloalkyl group; R